Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
2.
Chest ; 143(2): 532-538, 2013 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-23381318

RESUMO

Ultrasound guidance enables visualization of the needle insertion site for thoracentesis and paracentesis. The improved accuracy of needle placement using ultrasound may reduce risk of complications and their costs associated with these procedures. Using claims data from the Premier Perspective hospital database from January 1, 2007, through December 31, 2008, we conducted an observational cohort study examining the effect of ultrasound guidance on risk of pneumothorax among patients undergoing thoracentesis and on risk of bleeding complications after paracentesis. Patients at elevated risk of these outcomes for reasons beyond the procedure of interest were excluded. Adjusted risk of events was assessed using multivariate logistic regression controlling for patient and hospitalization characteristics. Hospitalization cost and length of stay (LOS) were estimated using multivariate ordinary least squares regression of log-transformed values. We analyzed 61,261 thoracentesis and 69,859 paracentesis patient records. Approximately 45% of these procedures were ultrasound guided. Pneumothorax occurred in 2.7% (n = 1,670) of patients undergoing thoracentesis. Of patients undergoing paracentesis, 0.8% (n = 565) experienced bleeding complications. After adjustment, ultrasound guidance reduced the risk of pneumothorax after thoracentesis by 19% (OR, 0.81; 95% CI, 0.74-0.90) and by 68% for bleeding complications after paracentesis (OR, 0.32; 95% CI, 0.25-0.41). Pneumothorax increased the total cost of hospitalization by $2,801 (P < .001) and LOS by 1.5 days (P < .001). Bleeding complications increased cost by $19,066 (P < .0001) and LOS by 4.3 days (P < .0001). The data indicate that ultrasound guidance is associated with decreased risk of pneumothorax with thoracentesis and of bleeding complications with paracentesis. These complications resulted in measurable increases in hospitalization costs and LOS.


Assuntos
Custos de Cuidados de Saúde/estatística & dados numéricos , Hemorragia/epidemiologia , Paracentese/efeitos adversos , Pneumotórax/epidemiologia , Punções/efeitos adversos , Tórax , Ultrassonografia de Intervenção/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Feminino , Hemorragia/economia , Hospitalização/economia , Humanos , Incidência , Tempo de Internação/economia , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Paracentese/economia , Segurança do Paciente , Pneumotórax/economia , Punções/economia , Estudos Retrospectivos , Fatores de Risco , Ultrassonografia de Intervenção/economia , Adulto Jovem
3.
Drug Saf ; 29(11): 1069-75, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17061912

RESUMO

BACKGROUND AND OBJECTIVE: Automated database studies have become a cornerstone of drug safety assessment. To assess the reliability of automated data, we compared the hospitalisation and mortality rates among three similar studies of automated healthcare databases in North America. METHODS: Similar protocols were used to identify patients diagnosed with chronic obstructive pulmonary disease (COPD) who were treated with inhaled bronchodilators or inhaled corticosteroids in the Saskatchewan Health Database (SHD), the Kaiser Permanente Medical Care Program (KPMCP) of Northern California, and a proprietary automated insurance claims database available from i3 (formerly Ingenix). Automated data were used to compute incidence rates of total hospitalisation, cardiovascular (CV) hospitalisation and hospitalisation due to several specific types of CV outcomes. Record linkage with registries of vital statistics was used to identify deaths, obtain death certificates, and compute rates of total mortality, CV mortality and deaths due to certain CV outcomes. We compared rates in the i3 population with rates in the other two populations using age-adjusted rate ratio estimates and 95% CIs. RESULTS: The i3 cohort had approximately one-half the rates of total mortality, CV mortality and total hospitalisations, but twice the rate of CV hospitalisations, compared with each of the other two database cohorts. DISCUSSION: The unexpectedly higher rates of CV hospitalisations in the i3 population are inconsistent with its lower CV mortality, total mortality and total hospitalisation rates. This discrepancy is not readily explained by a higher prevalence of CV disease or procedures, random variation or confounding. Instead, high CV hospitalisation rates in the i3 population are consistent with a high rate of false-positive diagnoses recorded on insurance billing claims. CONCLUSION: These results underscore the importance of ensuring valid endpoints in automated claims databases.


Assuntos
Viés , Broncodilatadores/uso terapêutico , Reações Falso-Positivas , Glucocorticoides/uso terapêutico , Formulário de Reclamação de Seguro , Seguro Saúde/estatística & dados numéricos , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Intervalos de Confiança , Bases de Dados Factuais , Hospitalização/estatística & dados numéricos , Humanos , Registro Médico Coordenado , América do Norte/epidemiologia , Doença Pulmonar Obstrutiva Crônica/mortalidade , Sistema de Registros
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA